Related Experiment Video

Updated: Aug 12, 2025

Live Imaging and Quantification of Viral Infection in K18 hACE2 Transgenic Mice Using Reporter-Expressing Recombinant SARS-CoV-2
08:41

Live Imaging and Quantification of Viral Infection in K18 hACE2 Transgenic Mice Using Reporter-Expressing Recombinant SARS-CoV-2

Published on: November 5, 2021

2.9K

Compounding for the Treatment of COVID-19 and Long COVID, Part 1: Terminology, Mutations, and Variants

Mike Riepl1

  • 1Retired Compounding Pharmacist, Bismarck, North Dakota. flintlock@bis.midco.net.

International Journal of Pharmaceutical Compounding
|January 31, 2023
PubMed

Insights

Compounded preparations may offer customized treatments for COVID-19 (coronavirus disease 2019) and long COVID when commercial therapies are ineffective. This series explores SARS-CoV-2 variants and compounding strategies for patient recovery.

Area of Science:

  • Virology
  • Infectious Diseases
  • Pharmacology

Background:

  • COVID-19, caused by SARS-CoV-2, is a pandemic with severe short-term and long-term health effects.
  • Disease trajectory is influenced by social, economic, political factors, and individual beliefs.
  • Emerging SARS-CoV-2 variants challenge the effectiveness of existing vaccines and treatments.

Purpose of the Study:

  • To provide information on viral terminology and SARS-CoV-2 variants.
  • To introduce the concept of compounded preparations for COVID-19 and long COVID.
  • To present two formulations for customized compounds.

Main Methods:

  • Review of pertinent viral terminology and SARS-CoV-2 mutations.
  • Discussion of the challenges posed by viral variants to therapeutic effectiveness.
  • Presentation of novel compounded formulations.

Main Results:

  • Understanding viral terminology and variants is crucial for effective treatment.
  • Compounded preparations can offer customized therapeutic options.
  • Two specific formulations are proposed for acute and long-term COVID-19 effects.

Conclusions:

  • Customized treatments, including compounded preparations, are necessary for patients with COVID-19 and long COVID.
  • Compounding offers a viable alternative when commercial therapies fail.
  • This article serves as an introduction to compounding strategies for SARS-CoV-2 infection management.

More Related Videos

Author Spotlight: Advancements in Multiplex Detection of Respiratory Viruses03:53

Author Spotlight: Advancements in Multiplex Detection of Respiratory Viruses

Published on: November 10, 2023

1.3K
Nasal Brushing Sampling and Processing Using Digital High Speed Ciliary Videomicroscopy – Adaptation for the COVID-19 Pandemic09:03

Nasal Brushing Sampling and Processing Using Digital High Speed Ciliary Videomicroscopy – Adaptation for the COVID-19 Pandemic

Published on: November 7, 2020

4.9K

Related Concept Videos

Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
413
Chronic Obstructive Pulmonary Disease-V: Management01:29

Chronic Obstructive Pulmonary Disease-V: Management

Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
2.7K
Cystic Fibrosis: Management01:24

Cystic Fibrosis: Management

Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
209
Chronic Obstructive Pulmonary Disease-III: Symptoms and Complications.01:25

Chronic Obstructive Pulmonary Disease-III: Symptoms and Complications.

Understanding the variety of primary symptoms and systemic complications that characterize chronic obstructive pulmonary disease (COPD) is crucial for healthcare professionals.
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD:
2.9K
COPD: Pathogenesis and Clinical Features01:20

COPD: Pathogenesis and Clinical Features

Chronic obstructive pulmonary disease (COPD) is a group of lung conditions that progressively worsen over time, including chronic bronchitis and emphysema. This cluster of diseases collectively leads to a gradual and irreversible decline in lung function over time.
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
419
Viral Recombination00:57

Viral Recombination

Cells are sometimes infected by more than one virus at once. When two viruses disassemble to expose their genomes for replication in the same cell, similar regions of their genomes can pair together and exchange sequences in a process called recombination. Alternatively, viruses with segmented genomes can swap segments in a process called reassortment.
23.7K